Vol. 1 No. 8 (2021)
Reimbursement Recommendations

Upadacitinib (Rinvoq)

Published August 20, 2021

Key Messages

  • CADTH recommends that Rinvoq should be reimbursed by public drug plans for the treatment of active psoriatic arthritis (PsA) if certain conditions are met.
  • Rinvoq should only be reimbursed if it is prescribed by a rheumatologist or a clinician who has experience treating adult patients with active PsA and if it does not cost more than other biologic disease-modifying antirheumatic drugs (bDMARDs) or targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs).
  • Rinvoq should only be covered to treat adult patients with active PsA who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs) in a similar way to other bDMARDs currently reimbursed by public drug plans.